Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells

Cell Death and Disease

Volumn 4, Issue 9, 2013, Pages

  Chen, J ^a   Bi, H ^b,c   Hou, J ^b   Zhang, X ^b   Zhang, C ^b   Yue, L ^b   Wen, X ^b   Liu, D ^b   Shi, H ^b   Yuan, J ^d   Liu, J ^b   Liu, B ^e  

^a CANCER HOSPITAL   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Gefitinib; Mutant KRAS; NSCLC

Indexed keywords

ATORVASTATIN; CASPASE 3; CASPASE 7; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; K RAS PROTEIN; MEVALONIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPTANOIC ACIDS; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; PYRROLES; QUINAZOLINES; RAS PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885002612     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.312     Document Type: Article

References (35)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22
2. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: E17
3. Cox AD, Der CJ. Ras family signaling: Therapeutic targeting. Cancer Biol Ther 2002; 1: 599-606
4. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale C M et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-Amplified lung cancer. J Clin Invest 2006; 116: 2695-2706
5. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-Activating mutations. Cancer Res 2010; 70: 8715-8725
6. Yoon YK, Kim H P, Han SW, Oh do Y, Im SA, Bang Y J et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Mol Carcinog 2010; 49: 353-362
7. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma- rationale for comprehensive mutation profiling. Mol Cancer Ther 2012; 11: 485-491
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-430
9. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-Translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007; 6: 541-555
10. Lee J, Lee I, Han B, Park JO, Jang J, Park C et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011; 103: 674-688
11. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007; 13: 5480-5487
12. Chen J, Lan T, Hou J, Zhang J, An Y, Tie L et al. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1. Int J Biochem Cell Biol 2012; 44: 759-769
13. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004; 3: 465-472
14. Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: A review. Clin Lung Cancer 2006; 8: 30-38
15. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532
16. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006; 118: 209-214
17. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326
18. Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther 2011; 10: 336-346
19. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009; 15: 489-500
20. Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012; 148: 639-650
21. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 2012; 130: 1733-1744
22. Mistafa O, Stenius U. Statins inhibit Akt/PKB signaling via P2-7 receptor in pancreatic cancer cells. Biochem Pharmacol 2009; 78: 1115-1126
23. Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y et al. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranylpyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res 2011; 30: 74
24. Herrmann C. Ras-effector interactions: After one decade. Curr Opin Struct Biol 2003; 13: 122-129
25. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 2008; 90: 9-17
26. Park IH, Kim JY, Jung J I, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs 2010; 28: 791-799
27. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000
28. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003; 343: 425-430
29. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: Variations on a theme. Oncogene 2008; 27: 5497-5510
30. Ji Z, Mei FC, Xie J, Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007; 282: 14048-14055
31. Hung TM, Hu RH, Ho C M, Chiu YL, Lee JL, Jeng YM et al. Downregulation of alpha-fetoprotein expression by LHX4: A critical role in hepatocarcinogenesis. Carcinogenesis 2011; 32: 1815-1823
32. Ahn BY, Elwi AN, Lee B, Trinh DL, Klimowicz AC, Yau A et al. Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 2010; 70: 3013-3019
33. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15: 429-440
34. Liu B, Wang G, Yang J, Pan X, Yang Z, Zang L. Berberine inhibits human hepatoma cell invasion without cytotoxicity in healthy hepatocytes. PLoS ONE 2011; 6: E21416
35. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010; 18: 423-435